Johnson and Johnson Acquires Developer of IVD Technologies

Johnson & Johnson Nordic AB (Sollentuna, Sweden), a Johnson & Johnson company, has acquired Amic (Uppsala, Sweden), a privately held developer of in vitro diagnostic (IVD) technologies for use in point-of-care (POC) and near-patient settings. The company will pay approximately US$40 million during the second quarter of the year 2008 for the expenses of in-process research and development. Other terms of the transaction were not disclosed.

The acquisition will provide Ortho-Clinical Diagnostics, Inc., (Raritan, NJ, USA), a Johnson & Johnson company, with access to a high performance technology platform--currently in development--that complements its clinical laboratory, immunohematology, and donor screening businesses.

Amic was formed with the mission to develop and produce polymer microsystems. The company integrates different functions onto a single chip. The functions include nanofluidic and microfluidic channels, surface chemistry, electrical wave-guides and connectors, refractive and diffractive microoptics. It is developing technology that uses the chip-based microfluidic platform to enable fully quantitative, immunoassay tests in POC or near-patient settings. This next-generation technology represents an advance in an area of diagnostics where double-digit market growth is anticipated.

Ortho-Clinical Diagnostics provides in-vitro diagnostic products that give healthcare professionals worldwide the knowledge they need to make better treatment decisions sooner. The company serves the global transfusion medicine community with donor screening and blood typing products to help ensure every patient receives blood that is safe, the right type, and the right unit.


Related Links:
Johnson & Johnson Nordic AB
Amic
Ortho-Clinical Diagnostics